SurModics Inc.+$0.72 $11.65 A Rodman & Renshaw analyst upgraded the shares to "market perform," saying the share price already reflects the risks the medical technology company is facing. (Ticker: SRDX)
about the writer
Trust is at the core of a long-term financial planning relationship.
